Janux Therapeutics, Inc. (JANX)

Market Cap	1.01B -27.4%
Revenue (ttm)	24.00M +5,367.0%
Net Income	-102.59M
EPS	-1.64
Shares Out	61.14M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	473,051
Open	16.57
Previous Close	16.30
Day's Range	16.16 - 16.79
52-Week Range	12.12 - 35.34
Beta	2.52
Analysts	Strong Buy
Price Target	36.24 (+118.58%)
Est. Earnings	Nov 5, 2026

About JANX

Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms technology to treat patients with cancer. The company’s clinical candidates include JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer and the vasculature of other tumors; and JANX008...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 11, 2021
• Employees: 113
• Stock Exchange: NASDAQ
• Ticker Symbol: JANX
• Website: https://www.januxrx.com

Financial Performance

In 2025, Janux Therapeutics's revenue was $10.00 million, a decrease of -5.55% compared to the previous year's $10.59 million. Losses were -$113.63 million, 64.7% more than in 2024.

Analyst Summary

According to 18 analysts, the average rating for JANX stock is "Strong Buy." The 12-month stock price target is $36.24, which is an increase of 118.58% from the latest price.

Price Target

$36.24

(118.58% upside)

Analyst Consensus: Strong Buy

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Sep 29, 2026

Data Sources Report a data error